DXCM vs MDT Comparison: AI Score, Valuation, Performance and Upside
Compare DexCom's continuous glucose monitoring pure-play against Medtronic's diversified device portfolio on growth and margins.
Use this DexCom vs Medtronic comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
DXCM holds the edge across 3 of 5 key metrics in this comparison. DXCM has delivered stronger 1-year price return (+14.87% vs -1.51%), though MDT has the better forward P/E setup (14.24x vs 29.07x for DXCM). DXCM leads on both revenue growth (13.10%) and operating margin (24.33%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for MDT (+8.34%) than for DXCM (+3.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | DXCM | MDT |
|---|---|---|
| AI scorei | 52.1 | 41.2 |
| AI ranki | #414 | #1072 |
| Latest closei | $87.93 | $92.77 |
| 1M returni | -1.86% | +0.74% |
| 6M returni | +30.71% | +6.79% |
| 1Y returni | +14.87% | -1.51% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DXCM | MDT |
|---|---|---|
| 1Y ago | $11.5K (+15.0%) started 2025-09-17 | $9.81K (-1.9%) started 2025-09-17 |
| 5Y ago | $6.31K (-36.9%) started 2021-09-20 | $9.16K (-8.4%) started 2021-09-20 |
| 10Y ago | $37.79K (+277.9%) started 2016-09-19 | $17.2K (+72.0%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | DXCM | MDT |
|---|---|---|
| Market capi | $34.27B | $116.77B |
| Trailing P/Ei | 35.90 | 24.46 |
| Forward P/Ei | 29.07 | 14.24 |
| Price/Salesi | 8.19 | N/A |
| EV/Revenuei | 6.79 | 3.78 |
| Analyst targeti | $94.12 | $98.84 |
| Target upsidei | +3.63% | +8.34% |
| Metric | DXCM | MDT |
|---|---|---|
| Revenue growthi | 13.10% | 9.90% |
| Earnings growthi | 43.60% | 18.30% |
| EPS growthi | +43.60% | +18.30% |
| FCF margini | +20.55% | +12.72% |
| Operating margini | 24.33% | 22.05% |
| Profit margini | 20.12% | 13.20% |
| ROIC proxyi | 38.49% | 9.84% |
| Return on equityi | 38.49% | 9.84% |
| Dividend yieldi | N/A | 3.16% |
| Payout ratioi | 0.00% | 70.20% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 1.41 | 0.57 |
| Debt/equityi | 53.35 | 58.21 |
| Current ratioi | 1.73 | 2.13 |
| Quick ratioi | 1.37 | 1.36 |
Over the past year, DXCM and MDT have moved weakly in the same direction (correlation of 0.32), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | DXCM | MDT |
|---|---|---|---|
| 1Y | Growthi | +15.03% | -1.91% |
| CAGRi | +15.05% | -1.92% | |
| Volatilityi | 41.19% | 23.52% | |
| Sharpe ratioi | 0.44 | -0.16 | |
| Sortino ratioi | 0.63 | -0.23 | |
| Max drawdowni | 28.26% | 30.00% | |
| Current drawdowni | 4.78% | 11.94% | |
| Avg drawdowni | 10.65% | 12.63% | |
| Ulcer Indexi | 12.52% | 15.33% | |
| Max daily dropi | 14.63% | 5.11% | |
| Max wkly dropi | 17.22% | 7.05% | |
| 5Y | Growthi | -36.94% | -19.04% |
| CAGRi | -8.82% | -4.14% | |
| Volatilityi | 47.34% | 22.50% | |
| Sharpe ratioi | -0.04 | -0.28 | |
| Sortino ratioi | -0.06 | -0.38 | |
| Max drawdowni | 66.32% | 43.47% | |
| Current drawdowni | 45.99% | 20.61% | |
| Avg drawdowni | 40.59% | 26.62% | |
| Ulcer Indexi | 43.57% | 27.79% | |
| Max daily dropi | 40.66% | 7.26% | |
| Max wkly dropi | 42.68% | 11.81% | |
| 10Y | Growthi | +277.95% | +34.54% |
| CAGRi | +14.23% | +3.01% | |
| Volatilityi | 48.75% | 23.55% | |
| Sharpe ratioi | 0.43 | 0.05 | |
| Sortino ratioi | 0.62 | 0.07 | |
| Max drawdowni | 66.32% | 45.10% | |
| Current drawdowni | 45.99% | 22.90% | |
| Avg drawdowni | 27.99% | 17.79% | |
| Ulcer Indexi | 33.86% | 22.08% | |
| Max daily dropi | 40.66% | 12.82% | |
| Max wkly dropi | 42.68% | 19.36% |
| Category | DXCM | MDT |
|---|---|---|
| Company | DXCM | MDT |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States a… | Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.